Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of net revenue from collaboration arrangement

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2024			2023			2024			2023
Royalties    - RELVAR/BREO	$	53,980		$	54,454		$	106,118		$	105,337
Royalties    - ANORO	$	13,218			11,267		$	22,951			20,698
Total royalties		67,198			65,721			129,069			126,035
Less: amortization of capitalized fees paid		(3,456	)		(3,456	)		(6,912	)		(6,912	)
Total net royalty revenue	$	63,742		$	62,265		$	122,157		$	119,123